Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$86.50|
|52 Week High||US$62.00|
|52 Week Low||US$92.00|
|1 Month Change||2.37%|
|3 Month Change||23.57%|
|1 Year Change||22.24%|
|3 Year Change||147.14%|
|5 Year Change||167.22%|
|Change since IPO||28,732.18%|
Recent News & Updates
|BIOQ||US Life Sciences||US Market|
Return vs Industry: BIOQ underperformed the US Life Sciences industry which returned 35.7% over the past year.
Return vs Market: BIOQ underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: Insufficient data to determine BIOQ's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.
About the Company
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.
Bioqual Fundamentals Summary
|BIOQ fundamental statistics|
Is BIOQ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIOQ income statement (TTM)|
|Cost of Revenue||US$39.82m|
Last Reported Earnings
Aug 31, 2021
Next Earnings Date
|Earnings per share (EPS)||6.64|
|Net Profit Margin||10.20%|
How did BIOQ perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Is Bioqual undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BIOQ ($86.5) is trading above our estimate of fair value ($29.29)
Significantly Below Fair Value: BIOQ is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BIOQ is good value based on its PE Ratio (13x) compared to the US Life Sciences industry average (48x).
PE vs Market: BIOQ is good value based on its PE Ratio (13x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOQ's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOQ is good value based on its PB Ratio (2.3x) compared to the US Life Sciences industry average (6.1x).
How is Bioqual forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioqual has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Bioqual performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOQ has high quality earnings.
Growing Profit Margin: BIOQ's current net profit margins (10.2%) are higher than last year (9.1%).
Past Earnings Growth Analysis
Earnings Trend: BIOQ's earnings have grown by 9.5% per year over the past 5 years.
Accelerating Growth: BIOQ's earnings growth over the past year (27.1%) exceeds its 5-year average (9.5% per year).
Earnings vs Industry: BIOQ earnings growth over the past year (27.1%) underperformed the Life Sciences industry 56.9%.
Return on Equity
High ROE: BIOQ's Return on Equity (17.7%) is considered low.
How is Bioqual's financial position?
Financial Position Analysis
Short Term Liabilities: BIOQ's short term assets ($29.3M) exceed its short term liabilities ($8.5M).
Long Term Liabilities: BIOQ's short term assets ($29.3M) exceed its long term liabilities ($11.4M).
Debt to Equity History and Analysis
Debt Level: BIOQ is debt free.
Reducing Debt: BIOQ has no debt compared to 5 years ago when its debt to equity ratio was 5.7%.
Debt Coverage: BIOQ has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BIOQ has no debt, therefore coverage of interest payments is not a concern.
What is Bioqual current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIOQ's dividend (1.45%) is higher than the bottom 25% of dividend payers in the US market (1.29%).
High Dividend: BIOQ's dividend (1.45%) is low compared to the top 25% of dividend payers in the US market (3.47%).
Stability and Growth of Payments
Stable Dividend: BIOQ's dividends per share have been stable in the past 10 years.
Growing Dividend: BIOQ's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (18.8%), BIOQ's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mark Lewis (66 yo)
Dr. Mark G. Lewis, PhD has been the Chief Executive Officer and President of BIOQUAL, Inc. since June 3, 2013 and November 15, 2010 respectively. Dr. Lewis served as Director of Research at BIOQUAL Inc. F...
Experienced Board: BIOQ's board of directors are seasoned and experienced ( 29.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bioqual, Inc.'s employee growth, exchange listings and data sources
- Name: Bioqual, Inc.
- Ticker: BIOQ
- Exchange: OTCPK
- Founded: 1981
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$77.367m
- Shares outstanding: 894.42k
- Website: https://www.bioqual.com
- Bioqual, Inc.
- 9600 Medical Center Drive
- Suite 101
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 22:09|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.